In order to maintain homeostasis, cells interpret and coordinate responses to diverse environmental cues such as growth factors, energy status, and the availability of glucose and other nutrients. Mutations in the pathways that coordinate these responses can contribute to metabolic or inflammatory disorders and often promote tumorigenesis, as in tuberous sclerosis complex (TSC). TSC is an autosomal-dominant disorder that is characterized by the development of benign tumors, called hamartomas, in many vital organs including the brain, kidneys, heart, and lungs (reviewed in Kwiatkowski, 2003) . It has a prevalence of roughly 1 in every 10,000 births and results from mutations in either TSC1 or TSC2 (which encode proteins also called Hamartin and Tuberin, respectively). Recent studies in both flies and mammals have placed the TSC1/2 proteins in the middle of an evolutionarily conserved signaling pathway that controls mTOR, a serine/threonine kinase that stimulates ribosome biogenesis and protein synthesis (reviewed in Shaw and Cantley, 2006) . mTOR integrates distinct signals reflecting nutrient availability, presence of growth factors, and bioenergetic status into the regulation of cell growth and proliferation. Work by Guan and colleagues (Inoki et al., 2006 ) now reveals a pathway by which bioenergetic status and the Wnt pathway are integrated to control the activity of mTOR. They show that the sequential phosphorylation of TSC2 by AMP-activated protein kinase (AMPK), which is activated by low cellular energy, and glycogen synthase kinase 3 (GSK3), which is inhibited by Wnt signaling, stimulates the activity of TSC2, leading to the inhibition of mTOR.
TSC2 is an ?180 kDa protein that is phosphorylated on multiple sites (Figure 1 ) by various kinases. Depending on the site that is phosphorylated, the GAP (GTPase-activating protein) activity of TSC2 toward the small GTPase Rheb (a Ras homolog enriched in brain) is inhibited or activated. Rheb is a positive regulator of the mTORC1 complex (which consists of mTOR, Raptor, and mLST8) and is sensitive to rapamycin (Shaw and Cantley, 2006) . Although the precise mechanisms remain unclear, mitogen signaling inhibits the ability of TSC2 to negatively regulate Rheb, resulting in augmented mTORC1 signaling. For
The TSC1/2 tumor-suppressor complex controls protein synthesis through the regulation of mTOR. In this issue of Cell, Inoki et al. (2006) report that the kinases GSK3 and AMPK cooperate in the activation of TSC2 to inhibit mTOR activity. Surprisingly, the phosphorylation of TSC2 by GSK3 is markedly suppressed by Wnt signaling. This suggests that components of the mTOR pathway may be therapeutic targets for diseases linked to hyperactive Wnt signaling.
instance, Akt phosphorylates TSC2 at Ser939 and Thr1462, and mutation of these sites to Ala residues inhibits the ability of PI3K/Akt (stimulated by growth factors) to activate S6K1, a downstream effector of mTORC1 (Shaw and Cantley, 2006) . Recent evidence indicates that phosphorylation of TSC2 at Ser939 and Ser981 by Akt generates binding sites for the 14-3-3 protein that sequesters TSC2 away from TSC1 associated with endomembranes (Cai et al., 2006) . Additionally, phorbol esters and activated Ras mediate Akt-independent phosphorylation of TSC2 at Ser1798 and Ser664 via the kinases RSK and ERK, respectively, to activate mTORC1 (Roux et al., 2004; Ma et al., 2005) . Conversely, under energetic stress or increasing AMP levels, the tumor suppressor LKB1 phosphorylates AMPK, which in turn phosphorylates TSC2 at Ser1345 to promote its GAP activity toward Rheb (Inoki et al., 2003) . Two other sites in TSC2 (Ser1337 and Ser1341) were also found to require priming by AMPK through phosphorylation of Ser1345; however, the identity of the kinase catalyzing phosphorylation of these sites has remained unclear until now.
Inoki et al. show that GSK3α and β cooperate with AMPK to phosphorylate Ser1341 and Ser1337. Indeed, GSK3 typically requires priming through phosphorylation of sites located 4 residues C-terminal to its phosphorylation site (Patel et al., 2004) . Thus, phosphorylation at Ser1345 by AMPK was found to prime GSK3 phosphorylation of Ser1341 and Ser1337. More importantly, the authors found that mutation of the GSK3 sites on TSC2 stimulated apoptosis upon glucose deprivation, which was a consequence of reduced TSC2 activity and enhanced mTORC1 activity. Taken together, the results of the new study suggest that inhibition of GSK3 may be necessary for mTORC1 activation.
Although the work by Inoki et al. identifies the kinase that cooperates with AMPK to inhibit mTORC1, it also raises several compelling questions about the positive and negative inputs that regulate TSC2. As has been shown, simultaneous activation of AMPK and PI3K/Akt inhibits mTORC1 activation, suggesting that the input of AMPK into TSC2 is dominant and that its inhibition is absolutely necessary for mTORC1 activation (Hahn-Windgassen et al., 2005) . In light of recent findings concerning the mechanisms of TSC2 inactivation, phosphorylation of Ser1345 by AMPK may interfere with 14-3-3 binding and/or prevent the relocalization of TSC2 and its dissociation from TSC1 following stimulation by growth factors. Thus, the question remains: Is inhibition of GSK3, which is often observed following growth-factor stimulation, also required for mTORC1 activation? To address this, Inoki et al. showed that overexpression of a constitutively active GSK3β in cells growing in serum is sufficient to inhibit S6K1 activation, suggesting that loss of GSK3 activity is required for mTORC1 activation. The authors also show that RNAi-mediated knockdown or chemical inhibition of GSK3 is sufficient to activate mTORC1/S6K1. It is intriguing that both Akt and RSK, two kinases implicated in TSC2 phosphorylation, are also able to phosphorylate and inhibit GSK3 (Patel et al., 2004) . Although Inoki et al. do show that the inhibition of GSK3 can act cooperatively with insulin (which stimulates the PI3K/Akt pathway) to further increase S6K1 activation, the authors did not investigate whether (A) The tumor-suppressor protein TSC2 is phosphorylated by several different kinases, including Akt, ERK, and RSK, which repress the ability of TSC2 to function as a GAP (GTPase-activating protein) toward the small GTPase Rheb. Akt-mediated phosphorylations at Ser939 and Ser981 are thought to create binding sites for 14-3-3, which sequesters TSC2 away from TSC1 and Rheb. Conversely, AMPK-mediated phosphorylation of Ser1345 and subsequent GSK3-dependent phosphorylation of Ser1337 and Ser1341 positively regulate the ability of TSC2 to function as a GAP toward Rheb. The mechanism by which phosphorylations on Ser1798 (RSK), Ser664 (ERK), and Thr1462 (Akt) of TSC2 can negatively regulate its GAP activity toward Rheb remains unclear. (B) The TSC protein complex might be regulated by members of the β-catenin "destruction complex." Upon energetic stress and GSK3 activation, TSC1 and TSC2 are localized at endomembranes, where TSC2 functions as a GAP toward Rheb to inhibit mTOR. This effect requires phosphorylation by the kinases AMPK and GSK3, which may also require Axin, a member of the β-catenin destruction complex. Conversely, upon growth-factor activation, TSC2 is phosphorylated by various kinases that lead to its dissociation from TSC1 and the endomembranes. The cytosolic TSC2 could be bound to 14-3-3 and/or Dishevelled, which negatively regulates the activity of GSK3. a constitutively active GSK3 can inhibit S6K1 activation induced by insulin. Therefore, whether the inhibition of GSK3 via Akt or RSK is also necessary for the activation of mTORC1 by insulin or phorbol ester remains to be determined.
Importantly, the authors link the Wnt signaling pathway to the inhibition of GSK3. The Wnt signaling pathway is involved in cellular proliferation, survival, and fate determination and is especially critical during developmental processes. In the absence of Wnt signaling, β-catenin is degraded via its recruitment to the "destruction complex" that includes adenomatous polyposis coli (APC), Axin, PP2A, CK1, and GSK3. β-catenin is phosphorylated by CK1 and GSK3, allowing it to be recognized by β-TrCP and subsequently ubiquitinated and targeted for proteolysis. Wnt proteins bind to the Frizzled (Fz)/LRP receptor complex at the cell surface, which transduces a signal to Dishevelled (Dsh) and Axin. As a consequence, the degradation of β-catenin is inhibited. This promotes the accumulation of β-catenin in the nucleus, where it can interact with LEF/TCF transcription factors to stimulate expression of pro-growth genes such as cyclin D and c-myc. Mutations in APC, Axin, and β-catenin that promote the stabilization of β-catenin are found in many different cancers, indicating that constitutive Wnt signaling is a common feature in many neoplasms (Reya and Clevers, 2005) . Through an enormous amount of data, Inoki et al. show that Wnt-mediated signaling activates mTORC1 and is critical for tumors induced by mouse mammary tumor virus (MMTV) LTR-driven expression of Wnt-1. They show that mTORC1 activation by Wnt is sensitive to rapamycin, an mTORC1 inhibitor, but did not require activities from Akt, ERK1/2, or β-catenin-dependent transcription. Fittingly, Wnt stimulation of mTORC1 activity required the TSC protein complex and inhibition of GSK3. It should be noted that, upon Wnt stimulation, the inhibition of GSK3 that is part of the destruction complex occurs via a mechanism that is distinct from its inhibition by the kinases Akt and RSK (McManus et al., 2005) .
Members of the destruction complex also associate with TSC1/2. Although Axin and GSK3 dissociate from TSC2 upon Wnt stimulation, Dsh interacts with TSC2 following stimulation by Wnt (Mak et al., 2005) . Consistent with these observations, Inoki et al. also show that overexpression of Dsh stimulates activation of S6K1 and that this effect is more pronounced under glucose starvation. This may be because activated AMPK primes TSC2 for phosphorylation by GSK3 under these low-energy conditions. However, whether members of the destruction complex are functionally required for the recruitment of GSK3 and the subsequent phosphorylation of TSC2 remains to be determined ( Figure 1B) . It does seem likely that members of the destruction complex could provide scaffolding functions, as both overexpression and RNAi-mediated knockdown of Axin are reported to inhibit S6K1 activity. In addition, there might also be mutually exclusive complexes that differentiate between active TSC2 (which is associated with TSC1) versus inactive TSC2. Although GSK3 interacts with both TSC1 and TSC2, it appears that Dsh only associates with TSC2 (Mak et al., 2005) . Upon Wnt stimulation, TSC1 and TSC2 could dissociate. This dissociation may correlate with the loss of the interaction between Axin/GSK3 and TSC2 and may coincide with the association of Dsh with TSC2 ( Figure 1B) . Conversely, it seems unlikely that mere recruitment of GSK3 to endomembranes, where the active TSC complex is located, is sufficient for TSC2 phosphorylation. This is because Wnt stimulation and activation of LRP leads to the recruitment of GSK3 to the membrane independently of the destruction complex (Zeng et al., 2005) . Although speculative, the integration of the destruction complex onto endomembranes via the TSC protein complex may provide insights into how the energy input into mTORC1 is regulated.
From a clinical standpoint, the work by Guan and colleagues (Inoki et al., 2006 ) also provides a new therapeutic target for cancers that are dependent on the Wnt signaling pathway. Although this remains to be determined, rapamycin may prove to be efficacious for the treatment of tumors "addicted" to the Wnt signaling pathway. Tumors may have "evolved" a mechanism to control both the transcription and translation of genes that promote growth in order to meet biosynthetic demand. Surprisingly, in the case of the Wnt pathway, inhibition of GSK3 may be involved in controlling both mechanisms.
